Antidepressants and cognitive-behavioral therapy for symptom syndromes

CNS Spectrums

Volumn 11, Issue 3, 2006, Pages 212-222

  Jackson, Jeffrey L ^a,e   O'Malley, Patrick G ^b   Kroenke, Kurt ^c,d  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d REGENSTRIEF INSTITUTE   (United States)

^e UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; CYCLOBENZAPRINE; DESIPRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DULOXETINE; FLUOXETINE; GABAPENTIN; IMIPRAMINE; MAPROTILINE; MOCLOBEMIDE; MUSCLE RELAXANT AGENT; N (5 BENZAMIDO 4 OXO 6 PHENYLHEXANOYL)PROLINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; NORTRIPTYLINE; OPIATE; PAROXETINE; PHENELZINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

ANXIETY DISORDER; BACKACHE; BEHAVIOR THERAPY; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FACE PAIN; FIBROMYALGIA; HEADACHE; HUMAN; INTERSTITIAL CYSTITIS; IRRITABLE COLON; MENOPAUSAL SYNDROME; META ANALYSIS; MIGRAINE; NEUROPATHOLOGY; PAIN; PELVIS PAIN SYNDROME; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SOMATIZATION; SYSTEMATIC REVIEW; THORAX PAIN; TINNITUS;

EID: 33645215942     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900014383     Document Type: Review

References (134)

1. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122:1140-1156
2. Lake AE 3rd, Rains JC, Penzien DB, Lipchik GL. Headache and psychiatric comorbidity: historical context, clinical implications, and research relevance. Headache. 2005;45:493-506.
3. Patten SB, Beck CA, Kassam A, Williams JV, Barbui C, Metz LM. Long-term medical conditions and major depression: strength of association for specific conditions in the general population. Can J Psychiatry. 2005;50:195-202.
4. Bonaz B, Baciu M, Papillon E, et al. Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study. Am J Gastroenterol. 2002;97:654-656.
5. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125:19-31.
6. Jackson JL. Somatic and vegetative symptoms in depression. Depression, Mind and Body. 2004;1:42-49.
7. Damatarca C. Pain and depression: bridging the body and mind. Depression, Mind and Body. 2003;1:7-13.
8. Jones SL. Descending noradrenergic influences on pain. Prog Brain Res. 1991;88:391-394.
9. Richardson BP. Serotonin and nocioception. Ann N Y Acad Sci. 1990;600:511-519.
10. Stahl SM. The psychopharmacology of painful physical symptoms in depression. J Clin Psychiatry. 2002;63:382-383.
11. Willis WD, Westlund KN. Neuroanatomy of the pain system and the pathways that modulate pain. J Clin Neurophysiol. 1997;14:2-31.
12. Naliboff BD, Munakata J, Fullerton S, et al. Evidence for two distinct perceptual alterations in irritable bowel syndrome. Gut. 1997;41:505-512.
13. Petzke F, Harris RE, Williams DA, Clauw DJ, Gracely RH. Differences in unpleasantness induced by experimental pressure pain between patients with fibromyalgia and healthy controls. Eur J Pain. 2005;9:325-335.
14. Montoya P, Pauli P, Batra A, Wiedemann G. Altered processing of pain-related information in patients with fibromyalgia. Eur J Pain. 2005;9:293-303.
15. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8:159-166.
16. Kroenke K, Swindle R. Cognitive-behavioral therapy for somatization and symptom syndromes: a critical review of controlled clinical trials. Psychother Psychosom. 2000;69:205-215.
17. Allen LA, Escobar JI, Lehrer PM, Gara MA, Woolfolk RL. Psychosocial treatments for multiple unexplained physical symptoms: a review of the literature. Psychosom Med. 2002;64:939-950.
18. Lackner JM, Lou Coad M, Mertz HR, et al. Cognitive therapy for irritable bowel syndrome is associated with reduced limbic activity, GI symptoms, and anxiety. Behav Res Ther. 2005 Jul 20: [Epub ahead of print].
19. Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97(11 suppl):S7-S26.
20. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome: the view from general practice. Eur J Gastroenterol Hepatol. 1997;9:689-692.
21. Gladman LM, Gorard DA. General practitioner and hospital specialist attitudes to functional gastrointestinal disorders. Aliment Pharmacol Ther. 2003;17:651-654.
22. American College of Gastroenterology Functional Gastrointestinal Disorders Task Froce. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97(11 Suppl):S1-S5.
23. Guilera M, Balboa A, Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol. 2005;100:1174-1184.
24. Koloski NA, Talley NJ, Boyce PM. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. Am J Gastroenterol. 2001;96:1340-1349.
25. Clouse RE. Antidepressants for irritable bowel syndrome. Gut 2003;52:598-599.
26. Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum AL. Meta-analysis: The treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20:1253-69.
27. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med. 2000;133:136-147.
28. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med. 2000;108:65-72.
29. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care. 1989;27(3 suppl):S178-S189.
30. Tabas G, Beaves M, Wang J, Friday P, Mardini H, Arnold G. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol. 2004;99:914-920.
31. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol. 2003;1:219-228
32. Toner BB, Segal ZV, Emmot S, et al. Cognitive-behavioral group therapy for patients with irritable bowel syndrom. Int J Group Psychother. 1998;48:215-243.
33. Hutton J. Cognitive behaviour therapy for irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2005;17:11-14
34. Kennedy T, Jones R, Darnley S, Seed P, Wessely S, Chalder T. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. BMJ. 2005;331:435.
35. Shaw G, Srivastava ED, Sadlier M, Swann P, James JY, Rhodes J. Stress management for irritable bowel syndrome: a controlled trial. Digestion. 1991;50:36-42.
36. Bennett P, Wilkinson S. A comparison of psychological and medical treatment of the irritable bowel syndrome. Br J Clin Psychol. 1985;24(pt 3):215-216.
37. Heymann-Monnikes I, Arnold R, Florin I, Herda C, Melfsen S, Monnikes H. The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol. 2000;95:981-994.
38. Boyce PM, Talley NJ, Balaam B, Koloski NA, Truman G. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am J Gastroenterol. 2003;98:2209-2218.
39. Hart LG, Deyo RA, Gherkin DC, Hart LG, Deyo RA, Gherkin DC. Physician office visits for low back pain. Frequency, clinical evaluation, and treatment patterns from a U.S. national survey. Spine. 1995;20:11-19.
40. Maniadakis N, Gray A. The economic burden of back pain in the UK. Pain 2000;84:95-103.
41. Von Korff M, Saunders K. The course of back pain in primary care. Spine. 1996;21:2833-2837.
42. Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain: a meta-analysis. Arch Intern Med. 2002;162:19-24.
43. Staiger TO, Gaster B, Sullivan MD, Deyo RA. Systematic review of antidepressants in the treatment of chronic low back pain. Spine. 2003;28:2540-2545.
44. Schnitzer TJ, Ferraro A, Hunsche E, Kong SX. A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back pain. J Pain Symptom Manage. 2004;28:72-95.
45. Jenkins DG, Ebbutt AF, Evans CD. Tofranil in the treatment of low back pain. J Int Med Res. 1976;4(2 Suppl):28-40.
46. Alcoff J, Jones E, Rust P, et al. Controlled trial of imipramine for chronic low back pain. J Fam Pract. 1982;14:841-846.
47. Pheasant H, Bursk A, Goldfarb J, et al. Amitriptyline and chronic low-back pain. A randomized doubleblind crossover study. Spine. 1983;8:552-557.
48. Goodkin K, Gullion CM, Agras WS. A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome. J Clin Psychopharmacol. 1990;10:269-278.
49. Atkinson JH, Slater MA, Williams RA, et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain. 1998;76:287-296.
50. Atkinson JH, Slater MA, Wahlgren DR, et al. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain. 1999;83:137-145.
51. Dickens C, Jayson M, Sutton C, Creed F. The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain. Psychosomatics. 2000;41:490-499.
52. Ward N, Bokan JA, Phillips M, Benedetti C, Butler S, Spengler O. Antidepressants in concomitant chronic back pain and depression: doxepin and desipramine compared. J Clin Psychiatry. 1984;45(3 pt 2):54-59.
53. Schreiber S, Vinokur S, Shavelzon V, Pick CG, Zahavi E, Shir Y. A randomized trial of fluoxetine versus amitriptyline in musculo-skeletal pain. Isr J Psychiatry Relat Sci. 2001;38:88-94.
54. Hameroff SR, Weiss J, Lerman JC, et al. Doxepin's effects on chronic pain and depression. J Clin Psychiatry. 1984;45(3 pt2):47-52.
55. O'Malley PG, Jackson JL, Tomkins G, Santoro J, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes: a critical review. J Fam Pract. 1999;48:980-993.
56. Jung AC, Staiger T, Sullivan M. The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. J Gen Intern Med. 1997;12:384-389.
57. Dnghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain. 1992;49:205-219.
58. Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy. 2004;24:621-629.
59. Raine R, Haines A, Sensky T, Hutchings A, Larkin K, Black N. Systematic review of mental health interventions for patients with common somatic symptoms: can research evidence from secondary care be extrapolated to primary care? BMJ. 2002;325:1082.
60. van Tulder MW, Koes BW, Bouter LM. Conservative treatment of acute and chronic nonspecific low back pain. A systematic review of randomized controlled trials of the most common interventions. Spine. 1997;22:2128-2156.
61. Lorig KR, Holman H. Self-management education: history, definition, outcomes, and mechanisms. Ann Behav Med. 2003;26:1-7.
62. Rasmussen BK, Olesen J. Epidemiology of headache in a general population: a prevalence study. Curr Opin Neurol. 1994;7:264-227.
63. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159:813-818.
64. Taylor FR. Diagnosis and classification of headache. Prim Care. 2004;31:243-259.
65. Lake AE 3rd, Rains JC, Penzien DB, Lipchik GL. Headache and psychiatric comorbidity: historical context, clinical implications, and research relevance. Headache. 2005;45:493-506.
66. Gesztelyi G, Bereczki D. Disability is the major determinant of the severity of depressive symptoms in primary headaches but not in low back pain. Cephalalgia. 2005;25:598-604.
67. Torelli P, D'Amico D. An updated review of migraine and co-morbid psychiatric disorders. Neurol Sci. 2004;25(suppl 3):S234-S235.
68. Tomkins GE, Jackson JL, D'Malley PG, Balden E, Santoro JE. Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med. 2001;111:54-63.
69. Lance JW, Curran DA. Treatment of chronic tension headache. Lancet. 1964;1:1236-1239.
70. Moja PL, Cusi C, Sterzi RR, Canepari C. Selective Serotonin Re-uptake Inhibitors for Preventing Migraine and Tension-Type Reaches. Cochrane Database Syst Rev. 2005:CD002919.
71. Rains JC, Penzien DB, McCrory DC, Gray RN. Behavioral Headache Treatment: History, Review of the Empirical Literature, and Methodological Critique. Headache. 2005;45(suppl 2):S92-S109.
72. Linde, K. Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004;(4):CD003225.
73. Melchart D, Streng A, Hoppe A, et al. Acupuncture in patients with tension-type headache: randomised controlled trial. BMJ. 2005;331:376-382.
74. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754-762.
75. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001;322:19-22.
76. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289:65-69.
77. Ernst E. Manual therapies for pain control: chiropractic and massage. Clin J Pain. 2004;20:8-12.
78. Yunus MD, Kalayan-Raman UP, Masi AT, Aldag AT. Electron microscopic studies of muscle biopsy in primary fibromyalgia syndrome: a controlled and blinded study. J Rheumatol. 1989;16:97-10
79. Simms RW, Roy SH, Hrovat M, et al. Lack of association between fibromyalgia syndrome and abnormalities and muscle energy metabolism. Arthritis Rheum. 1994;37:794-800.
80. Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum. 1997;40:1928-1939
81. Wolfe F. Fibromyalgia: the clinical syndrome. Rheum Dis Clin North Am. 1989;15:1-17
82. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292:2388-2395.
83. Arroyo JF, Cohen ML. Abnormal responses to electrocutaneous stimulation in fibromyalgia. J Rheumatol. 1993;20:1925-1931.
84. Kosek E, Ekholm J, Hansson P. Modulation of pressure pain thresholds during and following isometric contraction in patients with fibromyalgia and in healthy controls. Pain. 1996;64:415-423.
85. Kosek E, Ekholm J, Hansson P. Increased pressure pain sensibility in fibromyalgia patients is located deep in the skin but not restricted to muscle tissue. Pain. 1995;63:335-339.
86. Drewes AM, Gade K, Nielsen KO, Bjerregard K, Taagholt SJ, Svendsen L. Clustering of sleep electroencephalographic patterns in patients with the fibromyalgia syndrome. Br J Rheumatol. 1995;34:1151-1156.
87. May KP, West SG, Baker MR, Everett DW. Sleep apnea in male patients with the fibromyalgia syndrome. Am J Med. 1993;94:505-508.
88. Yunus MB, Aldag JC. Restless leg syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ. 1996;312:1339.
89. MacFarlane JG, Shahal B, Mously C, Moldofsky H. Periodic K-alpha sleep EEG activity and periodic limb movements during sleep: comparisons of clinical features and sleep parameters. Sleep. 1996;19:200-204.
90. Hudson JL, Goldenberg DL, Pope HG Jr, Keck PE Jr, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med. 1992;92:363-367.
91. Triadafilopoulos G, Simms RW, Goldenberg DL. Bowel dysfunction in fibromyalgia syndrome. Dig Dis Sci. 1991;36:59-64.
92. Ahles TA, Khan SA, Yunus MB, Spiegell DA, Masi AT. Psychiatric status of patients with primary fibromyalgia, patients with rheumatoid arthritis and subjects without pain: a blind comparison of DSM-III diagnoses. Am J Psychiatry. 1991;148:1721 -1726.
93. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med. 2000;15:659-666.
94. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind, crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39:1852-1859.
95. Carette S, McCain GA, Bell DA, Fam AG. Evaluation of amitriptyline in primary fibrositis. A double-blind placebo-controlled study. Arthritis Rheum. 1986;29:655-659.
96. Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol. 1998;37:1279-1286.
97. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol. 1994;23:255-259.
98. Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995;61:445-449.
99. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112:191-197.
100. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974-2984.
101. Williams DA. Psychological and behavioural therapies in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol. 2003;17:649-665.
102. Hadhazy VA, Ezzo J, Creamer P, Berman BM. Mind-body therapies for the treatment of fibromyalgia. A systematic review. J Rheumatol. 2000;27:2911-2918.
103. Tofferi JK, O'Malley PG, Jackson JL. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum. 2004;51:9-13.
104. Sharpe M, O'Malley PG. Chronic fatigue and fibromyalgia syndromes. In: Levinson J, ed. Textbook of Consultation-Liaison Psychiatry, 1st ed. Washington, DC: American Psychiatric Press: 2004:108-134
105. Fukuda K, Straus SE, Hickie IB, Sharpe M, Dobbins JG, Komaroff AL. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121:953-959.
106. Sullivan PF, Pedersen NL, Jacks A, Evengard B. Chronic fatigue in a population sample: definitions and heterogeneity. Psychol Med. 2005;35:1337-1348.
107. Darbishire L, Ridsdale L, Seed PT. Distinguishing patients with chronic fatigue from those with chronic fatigue syndrome: a diagnostic study in UK primary care. Br J Gen Pract. 2003;53:441-445.
108. Whiting P, Bagnall AM, Sowden AJ, Cornell JE, Mulrow CD, Ramirez G. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. JAMA. 2001;286:1360-1368.
109. Natelson BH, Cheu J, Pareja J, Ellis SP, Policastro T, Findley TW. Randomized, bouble blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. Psychopharmacology. 1996;124:226-230.
110. Vercoulen JH, Swanink CM, Zitman FG, et al. Randomized double-blind placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet. 1996;347:858-861.
111. Hickie IB, Wilson AJ, Wright JM, Bennet BK, Wakefield O, Lloyd AR. A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. J Clin Psychiatry. 2000;61:643-648.
112. Wearden AJ, Morriss RK, Mullis R, el al. Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome. Br J Psychiatry. 1998;172:485-490.
113. Sharpe M, Hawton K, Simkin S, et al. Cognitive behavior therapy for the chronic fatigue syndrome: a randomised controlled trial. BMJ. 19963;12:22-26.
114. Deale A, Chalder T, Marks I, Wessely S. Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. Am J Psychiatry. 1997;154:408-414.
115. Lloyd AR, Hickie I, Brockman A, et al. Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. Am J Med. 1993;94:197-203.
116. Friedberg F, Krupp LB. A comparison of cognitive behavior treatment for chronic fatigue syndrome and primary depression. Clin Infect Dis. 1994;18(suppl 1):S105-S110.
117. Stulemeijer M, de Jong LW, Fiselier TJ, Hoogveld SW, Bleijenberg G. Cognitive behaviour therapy for adolescents with chronic fatigue syndrome: randomised controlled trial. BMJ. 2005;330:14.
118. Huibers MJ, Beurskens AJ, Van Schayck CP, et al. Efficacy of cognitive-behavioural therapy by general practitioners for unexplained fatigue among employees: randomised controlled trial. Br J Psychiatry. 2004;184:240-246.
119. Ridsdale L, Darbishire L, Seed PT. Is graded exercise better than cognitive behaviour therapy for fatigue? A UK randomized trial in primary care. Psychol Med. 2004;34:37-49.
120. Deale A, Husain K, Chalder T, Wessely S. Long-term outcome of cognitive behavior therapy versus relaxation therapy for chronic fatigue syndrome: a 5-year follow-up study. Am J Psychiatry. 2001;158:2038-2042.
121. Sullivan M, Katon W, Russo J, Dobie R, Sakai C. A randomized trial of nortriptyline for severe chronic tinnitus. Effects on depression, disability, and tinnitus symptoms. Arch Intern Med. 1993;153:2251-2259.
122. Mihail RC, Crowley JM, Walden BE, Fishburne J, Reinwall JE, Zajtchuk JT. The tricyclic trimipramine in the treatment of subjective tinnitus. Ann Otol Rhinol Laryngol. 1988;97:120-123.
123. Kroner-Herwig B, Frenzel A, Fritsche G, Schilkowsky G, Esser G. The management of chronic tinnitus: comparison of an outpatient cognitive-behavioral group training to minimal-contact interventions. J Psychosom Res. 2003;54:381-389.
124. Zachriat C, Kroner-Herwig B. Treating chronic tinnitus: comparison of cognitive-behavioural and habituation-based treatments. Cogn Behav Ther. 2004;33:187-198.
125. Andersson G, Lyttkens L. A meta-analytic review of psychological treatments for tinnitus. Br J Audiol. 1999;33:201-210.
126. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashers: a randomized controlled trial. JAMA. 2003;289:2827-2834.
127. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flashes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol. 2005;105:161-166.
128. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer a randomised controlled trial. Lancet 2000;356:2059-2063.
129. Feinmann C, Harris M, Cawley R. Psychogenic facial pain: presentation and treatment. Br Med J (Clin Res Ed). 1984;288:436-438.
130. Cannon RO, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 1994;30:1411-1417.
131. Kisely S, Campbell LA, Skerritt P. Psychological interventions for symptomatic management of non-specific chest pain in patients with normal coronary anatomy. Cochrane Database Syst Rev. 2005:CD004101.
132. van Ophoven A, Pokupic S, Heinecke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol. 2004;172:533-536.
133. Engel CC Jr, Walker EA, Engel AL, Bullis J, Armstrong A. A randomized, double-blind crossover trial of sertraline in women with chronic pelvic pain. J Psychosom Res. 1998;44:203-207.
134. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med. 2003;65:528-533.